What is BillionToOne?
BillionToOne operates at the intersection of biotechnology and data science, focusing on the development of highly accurate molecular diagnostics. Its core innovation, the patent-pending QCT molecular counter platform, represents a significant technical breakthrough by enabling the precise counting of DNA molecules at the single-count level. This capability is currently applied to the UNITY platform, which provides noninvasive prenatal screening for conditions such as cystic fibrosis, spinal muscular atrophy, and various hemoglobinopathies.
By leveraging maternal blood samples to detect fetal cell-free DNA, BillionToOne is effectively lowering the barrier to entry for advanced genetic testing. The company's market position is defined by its commitment to making molecular diagnostics more accessible, efficient, and accurate, thereby addressing critical gaps in prenatal care and broader genetic health monitoring.
How much funding has BillionToOne raised?
BillionToOne has raised a total of $646.6M across 6 funding rounds:
Series A
$15M
Series B
$55M
Series C
$125M
Unspecified
$48.5M
Series D
$130M
IPO
$273.1M
Series A (2019): $15M with participation from 500 Startups Istanbul, Civilization Ventures, Pacific 8 Ventures, Hummingbird Ventures, Libertus Capital, NeoTribe Ventures, HOF Capital, and Y Combinator
Series B (2021): $55M, investors not publicly disclosed
Series C (2022): $125M supported by Baillie Gifford, Neotribe Ventures, Hummingbird Ventures, and Adams Street Partners
Unspecified (2022): $48.5M featuring Adams Street Partners, Baillie Gifford, Neotribe Ventures, Hummingbird Ventures, and Libertus Capital
Series D (2024): $130M, investors not publicly disclosed
IPO (2025): $273.1M, investors not publicly disclosed
Key Investors in BillionToOne
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
Hummingbird Ventures
Hummingbird VC is a global seed investment fund that focuses on investing in outlier founders at the earliest stages of their ventures, providing significant support throughout the company lifecycle.
Neotribe Ventures
Neotribe Ventures is a Silicon Valley-based venture capital firm that identifies and funds entrepreneurs developing breakthrough technologies with the potential to create transformative market movements.
What's next for BillionToOne?
Following the recent strategic investment, BillionToOne is well-positioned to accelerate the commercial expansion of its diagnostic suite. The company's strategic roadmap likely involves scaling the adoption of the UNITY platform across global healthcare systems and potentially diversifying its diagnostic applications into new therapeutic areas. Given the firm's history of attracting top-tier venture capital and institutional partners, the focus will likely shift toward operational excellence and the further validation of its QCT technology in clinical settings.
As the company matures, the emphasis will remain on maintaining its competitive advantage in molecular counting while navigating the complexities of the diagnostic regulatory environment. The continued support from its investor base provides the necessary runway to sustain long-term research and development initiatives, ensuring that BillionToOne remains at the forefront of the precision medicine revolution.
